October 5, 2015
J&J divestitutes Cordis to Cardinal Health for $2 billion
Johnson & Johnson has completed the divestiture of its Cordis business to Cardinal Health for an approximate value of $2 billion.
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
October 5, 2015
2015 Nobel Prize in Physiology or Medicine winners
The Nobel Assembly at Karolinska Institutet has today decided to award the 2015 Nobel Prize in Physiology or Medicine with one half jointly to William C. Campbell and Satoshi Ōmura for their discoveries concerning a novel therapy against infections caused by roundworm parasites and the other half to Youyou Tu for her discoveries concerning a novel therapy against Malaria.
October 5, 2015
William C. Campbell and Update Satoshi Ōmura, and Youyou Tu split the 2015 Nobel Prize in Physiology or Medicine
William C. Campbell and Satoshi Ōmura split Nobel prize in Physiology or Medicine 2015 with Youyou Tu, for discoveries regarding novel therapies for some of the most devastating parasitic diseases.
October 5, 2015
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo + Yervoy Regimen
Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab), for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.
October 5, 2015
Avita expands Compassionate Use IDE program for ReCell
FDA allows Avita to expand its Compassionate Use Investigational Device Exemption (IDE) program for ReCell.
October 5, 2015
FDA OKs Alcon’s AcrySof IQ Aspheric IOL with the UltraSert Pre-loaded Delivery System for patients undergoing cataract surgery
Novartis’s Alcon has received US Food and Drug Administration (FDA) approval for its AcrySof IQ Aspheric IOL with the UltraSert Pre-loaded Delivery System for patients undergoing cataract surgery.
October 2, 2015
FDA: Accelerated approval for Keytruda for patients with advanced (NSCLC) lung cancer
accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC)
October 2, 2015
Pfizer acquisition of GlaxoSmithKline’s vaccines Nimenrix and Mencevax
Pfizer Inc. has announced that it has completed the acquisition of GlaxoSmithKline’s quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax.
October 2, 2015
FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept
Novartis company has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) under the 351 (k) pathway for its proposed biosimilar to Amgen’s US-licensed Enbrel (etanercept) – a tumor necrosis factor alpha (TNF-alpha) inhibitor.